TY - JOUR
T1 - Evidence for an association between hairy cell leukemia and renal cell and colorectal carcinoma
AU - Nielsen, Bendt
AU - Braide, Inger
AU - Hasselbalch, Hans
PY - 1992/10/15
Y1 - 1992/10/15
N2 - Background. Hairy cell leukemia (HCL) has been associated with several disease states. In this study, a possible association is reported between HCL and renal cell carcinoma (RCC) and colorectal carcinoma (CRC). Methods. A retrospective study of the case records of 50 patients with HCL in a study of α‐interferon (α‐IFN) treatment of HCL. Results. Three of 50 patients with HCL studied had RCC, and 2 of these also had CRC. In addition, two other patients had CRC. The other malignant lesions developed either before or after the diagnosis of HCL. In all patients, the HCL responded to α‐interferon (α‐IFN), but in four patients, the second lesion was diagnosed during IFN treatment. Conclusions. These findings could indicate that IFN does not correct a possible common basic etiologic defect and shows that even early CRC and RCC do not respond to the IFN doses administered. These findings should be considered in future trials of IFN treatment of these diseases. The authors also recommend a reevaluation of the frequency of second malignant lesions in HCL; this may be important particularly with the increased survival in patients with HCL who receive a‐IFN treatment.
AB - Background. Hairy cell leukemia (HCL) has been associated with several disease states. In this study, a possible association is reported between HCL and renal cell carcinoma (RCC) and colorectal carcinoma (CRC). Methods. A retrospective study of the case records of 50 patients with HCL in a study of α‐interferon (α‐IFN) treatment of HCL. Results. Three of 50 patients with HCL studied had RCC, and 2 of these also had CRC. In addition, two other patients had CRC. The other malignant lesions developed either before or after the diagnosis of HCL. In all patients, the HCL responded to α‐interferon (α‐IFN), but in four patients, the second lesion was diagnosed during IFN treatment. Conclusions. These findings could indicate that IFN does not correct a possible common basic etiologic defect and shows that even early CRC and RCC do not respond to the IFN doses administered. These findings should be considered in future trials of IFN treatment of these diseases. The authors also recommend a reevaluation of the frequency of second malignant lesions in HCL; this may be important particularly with the increased survival in patients with HCL who receive a‐IFN treatment.
KW - colorectal carcinoma
KW - hairy cell leukemia
KW - interferon
KW - multiple primary neoplasm
KW - renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=0026688285&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19921015)70:8<2087::AID-CNCR2820700813>3.0.CO;2-P
DO - 10.1002/1097-0142(19921015)70:8<2087::AID-CNCR2820700813>3.0.CO;2-P
M3 - Article
C2 - 1394039
AN - SCOPUS:0026688285
VL - 70
SP - 2087
EP - 2090
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 8
ER -